EducationPhD University of Chicago, 2004 (Health Economics, Public Policy)
MS University of North Carolina (Chapel Hill), 1999 (Biostatistics)
MS University of Toledo, 1997 (Pharmaceutical Sciences)
BS Jadavpur University, 1995 (Pharmaceutical Sciences)
Contact Infoemail: firstname.lastname@example.org
web site: http://faculty.washington.edu/basua/
office: H-375Q, Health Sciences Building
Magnuson Health Sciences Center
1959 NE Pacific St.
Seattle, WA 98195-7630
campus box: 357630
Anirban Basu's work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research.
Currently the Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington, Basu also serves as faculty member in the Department of Health Services and as an adjunct in the Department of Economics. Previously, Basu taught on the faculty of the University of Chicago Department of Medicine, where he remains an external affiliate of the Center for Health and the Social Sciences.
In addition to his position as a faculty research fellow at the National Bureau of Economic Research, Basu is as an associate editor for Health Economics, Journal of Health Economics, and Observational Studies, and has served as panelist or speaker at many economics and health studies conferences, nationally and abroad.
Basu A, Barton LJ, Fischer H, Reynolds K, Arterburn DE, Barthold D, Courcoulas A, Crawford CL, Fedorka PN, Kim BB, Mun EC, Murali SB, Zane RE, Coleman KJ. Comparative effectiveness of gastric bypass and sleeve gastrectomy on predicted 10-year risk of cardiovascular disease 5 years after surgery. Surg Obes Relat Dis. 2022 Jun;18(6):716-726. doi: 10.1016/j.soard.2022.02.021. Epub 2022 Mar 9. PMID: 35397945
Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2022 May 16. pii: bloodadvances.2021006281. doi: 10.1182/bloodadvances.2021006281. [Epub ahead of print] PMID: 35575558
Chhatwal J, Basu A. Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing? Value Health. 2022 May;25(5):697-698. doi: 10.1016/j.jval.2022.02.002. Epub 2022 Mar 19. PMID: 35315330 PMCID: PMC8933136
Johnson KM, Jiao B, Bender MA, Ramsey SD, Devine B, Basu A. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. PLoS One. 2022 Apr 28;17(4):e0267448. doi: 10.1371/journal.pone.0267448. eCollection 2022. PMID: 35482721 PMCID: PMC9049306
Comparative effectiveness research is a growing field that aims to generate evidence to improve health care decisions for patients and providers. It examines the benefits and risks of different medical or healthcare interventions, including drugs and medical technology. The results of these comparison studies are used by medical professionals to make better informed healthcare decisions and thereby improve patient care.
- Analysis: Including race in clinical algorithms can both reduce and increase health inequities — it depends on what doctors use them for
- 536 New Coronavirus Cases In Washington; State Death Toll Drops
- ‘Flattening the curve’ saves more lives than thought
- Official Covid-19 fatalities may undercount pandemic's death toll by many hundreds in NW
- The Health 202: Why determining the coronavirus death rate is so tricky
- Scientists predicted that the coronavirus death rate would fall over time, but instead it doubled. Here's why it now hovers at 6%
- 8 countries have coronavirus death rates above 10%, either due to disaster or limited testing
- UW study shows staggering numbers of US COVID-19 infection, fatality rates
- Coronavirus on track to kill 1.3 per cent of infected in US, ‘conservative’ study finds
- Rural hospital closings cause mortality rates to rise, study finds
- Anirban Basu on panel that updated guide to caregivers’ decisions
- UW Professors Named American Statistical Association Fellows
- Study Examines Outcomes, Costs after Return Visits to ER
- Outcomes from patient hospitalization after return visits to ER
- Drug projected at $1 million has spark mulling installment plan (Bloomberg Business, )
- 2014's Best & Worst States at Combating the High Cost of Lung Cancer
- Politics Gets in the Way of Signing up for Health Insurance
- Political Polarization and Health Insurance
- Where Are U.S. Healthcare Costs Going?
- Project to Gauge Effects of Affordable Care Act in Washington State